Evidence map›Paper›PMID 40726114›Full record

ArticleCNS neuroscience & therapeutics2025

The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR.

Lizhi Li, Juanjuan Huang, Yaqin Xiang, Xuxiang Zhang, Qian Xu, Qiying Sun, Zhenhua Liu, Xinxiang Yan, Jinchen Li, Beisha Tang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lizhi LiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Juanjuan HuangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yaqin XiangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xuxiang ZhangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0009-0004-5213-9984
Qian XuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0002-5223-9967
Qiying SunDepartment of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0002-2031-8345
Zhenhua LiuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xinxiang YanDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jinchen LiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0001-5522-806X
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jifeng GuoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.ORCID 0000-0002-3658-3928

Funding

National Key Research and Development Program of China 2021YFC2502100the National Key Plan for Scientific Research and Development of China 2021YFC2501204the Technology Major Project of Hunan Provincial Science and Technology Department 2021SK1010
6 · The paper itself

Abstract

aimsThe study aimed to investigate the role of NUS1 variants in Parkinson's disease (PD) progression and evaluate plasma Nogo-B receptor (NgBR) as a potential biomarker.

methodsWe recruited 228 PD patients, including 38 with NUS1 variants (NUS1-PD) and 190 without (GU-PD), and all underwent at least two follow-up visits. Linear mixed-effects models assessed motor and non-motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.

resultsNUS1-PD demonstrated an earlier age at onset and more severe motor features than GU-PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off-medication) in NUS1-PD and GU-PD, but a slower progression rate of urinary function in NUS1-PD (p = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III (p = 0.006) and cognitive impairment (p = 0.010).

conclusionNUS1 variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.

Indexed as

Disease ProgressionParkinson DiseaseReceptors, Cell SurfaceAgedBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedMultiple System AtrophySupranuclear Palsy, ProgressiveBiomarkersNUS1 protein, humanReceptors, Cell Surfacedisease progressionNogo‐B receptorNUS1 geneParkinson's disease

Identifiers

PMID40726114
PMCPMC12304428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.